- Home
- RIGL vs NAVI Comparison
RIGL vs NAVI Comparison
Compare RIGL & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | NAVI |
|---|---|---|
| Founded | 1996 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 760.4M |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RIGL | NAVI |
|---|---|---|
| Price | $45.86 | $9.97 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 6 |
| Target Price | ★ $45.67 | $10.00 |
| AVG Volume (30 Days) | 206.3K | ★ 1.0M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 6.73% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | 0.44 |
| Revenue | ★ $294,282,000.00 | $271,000,000.00 |
| Revenue This Year | N/A | $76.23 |
| Revenue Next Year | $12.75 | $15.73 |
| P/E Ratio | $34.00 | ★ $22.78 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $7.33 |
| 52 Week High | $52.24 | $13.50 |
Technical Indicators
Market Signals| Indicator | RIGL | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 64.27 |
| Support Level | $40.05 | $7.91 |
| Resistance Level | $49.50 | $10.37 |
| Average True Range (ATR) | 1.45 | 0.32 |
| MACD | -0.61 | 0.03 |
| Stochastic Oscillator | 17.89 | 95.34 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.